pGIPZ-PD-L1-EGFP Citations (3)

Originally described in: Exosomal PD-L1 harbors active defense function to suppress T cell killing of breast cancer cells and promote tumor growth.
Yang Y, Li CW, Chan LC, Wei Y, Hsu JM, Xia W, Cha JH, Hou J, Hsu JL, Sun L, Hung MC Cell Res. 2018 Aug;28(8):862-864. doi: 10.1038/s41422-018-0060-4. Epub 2018 Jun 29. PubMed Journal

---

Articles Citing pGIPZ-PD-L1-EGFP

Articles
PD-L1 recruits phospholipase C and enhances tumorigenicity of lung tumors harboring mutant forms of EGFR. Ghosh S, Nataraj NB, Noronha A, Patkar S, Sekar A, Mukherjee S, Winograd-Katz S, Kramarski L, Verma A, Lindzen M, Garcia DD, Green J, Eisenberg G, Gil-Henn H, Basu A, Lender Y, Weiss S, Oren M, Lotem M, Geiger B, Ruppin E, Yarden Y. Cell Rep. 2021 May 25;35(8):109181. doi: 10.1016/j.celrep.2021.109181. PubMed
PD-LI promotes rear retraction during persistent cell migration by altering integrin beta4 dynamics. Wang M, Xiong C, Mercurio AM. J Cell Biol. 2022 May 2;221(5):e202108083. doi: 10.1083/jcb.202108083. Epub 2022 Mar 28. PubMed
Therapeutic blocking of VEGF binding to neuropilin-2 diminishes PD-L1 expression to activate antitumor immunity in prostate cancer. Wang M, Wisniewski CA, Xiong C, Chhoy P, Goel HL, Kumar A, Zhu LJ, Li R, St Louis PA, Ferreira LM, Pakula H, Xu Z, Loda M, Jiang Z, Brehm MA, Mercurio AM. Sci Transl Med. 2023 May 3;15(694):eade5855. doi: 10.1126/scitranslmed.ade5855. Epub 2023 May 3. PubMed

If you have published an article using this material, please email us at to have your article added to this page.